Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
By D. Wrapp, Nianshuang Wang, Kizzmekia S. Corbett, J. Goldsmith, C. Hsieh, O. Abiona, Barney S. Graham, J. McLellan. 2020
8,341 citations recorded by the source corpus.
Structure of the nCoV trimeric spike The World Health Organization has declared the outbreak of a novel coronavirus (2019-nCoV) to be a public health emergency of international concern. The virus binds to host cells through its trimeric spike glycoprotein, making this protein a key target for potential therapies and diagnostics. Wrapp et al. determined a 3.5-angstrom-resolution structure of the 2019-nCoV trimeric spike protein by cryo–electron microscopy. Using biophysical assays, the authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor. They also tested three antibodies known to bind to the SARS-CoV spike protein but did not detect binding to the 2019-nCoV spike protein. These studies provide valuable information to guide the development of medical counter-measures for 2019-nCoV. Science, this issue p. 1260 The overall structure of the 2019-nCoV spike (S) protein resembles that of SARS-CoV S, but 2019-nCoV S binds more tightly to the host receptor. The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern. The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics. To facilitate medical countermeasure development, we determined a 3.5-angstrom-resolution cryo–electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation. We also provide biophysical and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S. Additionally, we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs. The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.
Subfields: Infectious Diseases
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, positive): “…proteins (~30 mg purified protein per liter Expi293F cells) were ~20-fold higher than for the prefusion-stabilized S-2P trimer (Kirchdoerfer et al., 2018; Pallesen et al., 2017; Walls et al., 2020; Wrapp et al., 2020) (~1.5 mg/L), and increased to ~60 mg/L following promoter optimization.”
- SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness (2020, positive): “Vectors encoding MERS-CoV S-2P 1 and SARS-CoV S-2P 23 were generated as previously described with the following small amendments.”
- SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat (2020, result): “This conclusion is consistent with the wide spread of SARS-CoV-2 within a short period time and was also echoed by the finding that SARS-CoV-2 Spike (S) protein had 10- to 20-fold higher affinity to human angiotensin-converting enzyme 2 (ACE2) receptor than that of SARS-CoV based on the Cryo-EM stru”
- Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment (2020, background): “State-of-the-art cryo-EM experiments have revealed the full structure of the Spike (S) protein in the close [pdb id: 6VXX] (Walls et al., 2020) and open (prefusion) states [pdb id: 6VYB] (Wrapp et al., 2020).”
- Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients (2020, background): “Six patients (2, 5, 6, 7, 8, 9) with sufficient amount of sera and good neutralising capacity were then selected for further characterisation.”
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding (2020, neutral): “Although residues in these epitopes are constrained for stability even in our measurements on the isolated RBD, some of them likely exhibit additional constraint due to quaternary contacts made in the full spike trimer (Walls et al., 2020; Wrapp et al., 2020a; Yuan et al., 2020b).”
- Zoonotic origins of human coronaviruses (2020, background): “Indeed, a cryo-EM study indicates a 10-to 20-fold higher affinity of this binding than that between human ACE2 and SARS-CoV S protein [76] .”
- Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies (2020, background): “On the B cell side, in agreement with very recent experimental studies [47,48], our results suggest that SARS-CoV-derived antibodies targeting the receptor binding motif in the S1 subunit of the SARS-CoV-2 S protein may not be effective, due to the large genetic mismatches observed in known structur”
- COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives (2020, neutral): “The 3D structure of the viral S of 2019-nCoV determined by electron microscopy (Figure 3A, [61]) revealed its similarity to S of other CoVs.”